ISR Articles
-
Preferred Provider Use For IRT Services
In Q2, 2020, ISR asked 109 outsourcers of IRT services about their company’s use of preferred providers. Among respondents that are knowledgeable about their company’s preferred provider use, 44% currently have preferred provider agreements in place for IRT services. Among respondents with preferred providers for IRT services, their companies have an average of 2.7 preferred providers. On average, respondents reported that preferred providers complete 86% of all IRT work.
-
Insights Into The Competitive Clinical Manufacturing Market
There are perhaps too many options when it comes to choosing the right service provider for clinical manufacturing. Drug innovators weigh in on their selection metrics and preferences as well as reveal why vendors lose bids.
-
Top 5 Challenges In Finding Rare Disease Patients
ISR asked respondents with involvement in patient recruitment and retention activities for Phase 2/3 rare disease studies about their pain points regarding patient recruitment. Uncover the challenges that respondents say they face.
-
Influence Of Size In CRO Selection
ISR surveyed hundreds of clinical development outsourcers about what they consider important when selecting providers. To capture the increasing role that preferred provider agreements are playing in the selection process, respondents were asked about attribute importance in several scenarios.
-
Trends In Clinical Development
We asked 329 respondents from sponsor organizations to share their thoughts about a variety of current trends in the clinical development space. We analyzed responses by company size to understand how perspectives of respondents at large sponsors (those spending over $1B annually on R&D) differ from those at non-large organizations. Respondents were provided a list of trend-related statements and asked to rate their level of agreement with each.
-
Attributes Gaining Importance In Clinical Research
What sponsors need from their clinical research partners can shift year to year, which is why respondents were asked about which attributes they believe to be rising in importance when choosing between preferred providers. Explore the top three attributes gaining importance across all clinical phases.
-
CRO Selection Taken Seriously
Industry Standard Research (ISR) asked over 500 clinical-development outsourcers their level of agreement with the statement: My organization’s mix of CROs is not likely to change much in the next two years. This article not only offers insight into their responses, but also what is important to sponsors when looking to outsource clinical development work.
-
Old Dog, New Tricks: How Pharma Is Innovating With Existing Technologies
Innovation in clinical technologies sometimes comes in the shape of disruptive new technologies or as a series of incremental changes and improvements. Find out how new data is revealing positive changes and existing tech solutions are now being used in new ways.
-
Provider Selection In Small And Emerging Pharma Companies
As anyone who has ever attempted to sell clinical development services to pharma organizations can tell you, the task is no mean feat. It is difficult to determine who makes the decisions and who the influencers are. The presence of preferred provider agreements makes it tricky for a new provider to get its proverbial foot in the door. And, of course, every company has a different process for outsourcing clinical development work.
-
Technology In Clinical Trials: Differences By Company Size
When looking at industrywide trends, it’s helpful to remember that large sponsors have more resources to help them pursue new technology initiatives. With that in mind, explore where large vs. nonlarge sponsors differ in terms of openness to emerging trends in clinical development.